Savara to Showcase Molgramostim Data at CHEST 2026, Highlighting Long-Term Efficacy in Rare Lung Disease

  • Savara Inc. will present new data from the IMPALA clinical trials at CHEST 2026, including an encore oral presentation on long-term efficacy of molgramostim in aPAP patients.
  • The oral presentation will focus on results from the Phase 3 IMPALA-2 trial's open-label treatment period, scheduled for October 20, 2026.
  • A poster presentation will detail molgramostim's effects in aPAP patients with mild diffusion impairment, scheduled for October 21, 2026.
  • Bruce C. Trapnell, M.D., will lead both presentations, alongside patient speakers Eric and Karli.

Savara's presentations at CHEST 2026 come at a critical juncture for molgramostim, its lead candidate for autoimmune pulmonary alveolar proteinosis (aPAP). The focus on long-term efficacy and patient-specific outcomes aligns with broader industry trends emphasizing sustained therapeutic benefits in rare diseases. Success here could accelerate Savara's path to commercialization, though competition and regulatory hurdles remain.

Clinical Validation
Whether the long-term data from the IMPALA-2 trial will reinforce molgramostim's efficacy and safety profile in aPAP patients.
Regulatory Pathway
The pace at which Savara can advance molgramostim toward regulatory approval based on these trial results.
Market Differentiation
How Savara positions molgramostim against potential competitors in the rare respiratory disease space.